Triathlon Medical Ventures

Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.

Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

Alluxa, Inc. is a manufacturer of precision optical thin film interference filters, primarily serving markets in industrial technology, telecommunications, biomedical instruments, and semiconductors. Founded in 2007 and based in Santa Rosa, California, the company specializes in designing and building coating equipment that utilizes automation and proprietary control algorithms. Alluxa employs a patented plasma thin film deposition process, enabling the company to offer customized precision coating solutions that meet high-performance requirements while maintaining cost-efficiency for its clients. Formerly known as Sirrus Technology, Inc., Alluxa has established itself as a significant player in its industry.

Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

Tolera Therapeutics Inc. is a biotechnology company established under the leadership of Dr. Maria Siemionow, an expert in microsurgery and transplantation. Originating as a spin-off of the Cleveland Clinic, Tolera focuses on developing advanced immune modulation therapies aimed at enhancing organ and tissue transplant acceptance while minimizing the need for chronic immunosuppression. The company’s innovative approach targets the human alpha-beta T-cell receptor, which helps render pathologic T-cells inert. This unique signaling pathway promotes the expansion of regulatory T-cells in a non-depleting manner, addressing unmet medical needs for patients with a range of autoimmune and immune-mediated diseases. Through its research, Tolera Therapeutics aims to provide safer, more effective solutions that improve patient outcomes and quality of life.

Juventas Therapeutics, Inc. is a clinical-stage biotechnology company based in Cleveland, Ohio, founded in 2007. The company specializes in developing non-viral gene therapies aimed at activating the body's natural repair processes. Its primary focus is on treating non-healing wounds in patients with advanced peripheral artery disease. The flagship product, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1 (SDF-1), a signaling protein that helps recruit the body's stem cells and promotes tissue repair across various disease states. Juventas has transitioned its therapeutic platform from concept to the initiation of mid-stage clinical trials, underpinned by exclusive licensing from the Cleveland Clinic and supported by various investors and grants.

Mitralign is a privately held medical device company based in a suburb of Boston, Massachusetts. It specializes in developing catheter-based technologies for the percutaneous treatment of functional mitral regurgitation, a global and life-threatening cardiac condition. The company's innovative Mitralign system mimics surgical annuloplasty by delivering a series of implants directly into the mitral annulus via a catheter, reducing its size and improving valve function. Mitralign is backed by top-tier venture capitalists and has strategic investments from major cardiovascular device companies.

CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

Celleration Inc. is a privately held medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, utilizes low-frequency ultrasound delivered through a saline mist to promote healing in wounds. This innovative approach allows ultrasound energy to penetrate beyond the surface of the wound, stimulating cellular activity and enhancing the healing process. Since receiving FDA clearance in 2005, Celleration has established a strong presence in the U.S. market, with over 1 million MIST Therapy treatments performed, benefiting more than 65,000 patients across numerous healthcare facilities. Celleration's commitment to advancing wound care technology has resulted in significant clinical and economic benefits, reinforcing its role in the medical community.

Tolera Therapeutics Inc. is a biotechnology company established under the leadership of Dr. Maria Siemionow, an expert in microsurgery and transplantation. Originating as a spin-off of the Cleveland Clinic, Tolera focuses on developing advanced immune modulation therapies aimed at enhancing organ and tissue transplant acceptance while minimizing the need for chronic immunosuppression. The company’s innovative approach targets the human alpha-beta T-cell receptor, which helps render pathologic T-cells inert. This unique signaling pathway promotes the expansion of regulatory T-cells in a non-depleting manner, addressing unmet medical needs for patients with a range of autoimmune and immune-mediated diseases. Through its research, Tolera Therapeutics aims to provide safer, more effective solutions that improve patient outcomes and quality of life.

Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

BioVex Group is a biotechnology company specializing in the development and commercialization of biological treatments for cancer and infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine designed to target and destroy cancer cells while preserving surrounding healthy tissues. This innovative therapy utilizes a virus that replicates within solid tumors, leading to their destruction and stimulating a robust systemic immune response against the cancer. OncoVEXGM-CSF has undergone extensive clinical testing with over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and resulting in overall disease responses during Phase II trials. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes, further expanding its portfolio in biologic therapies.

Juventas Therapeutics, Inc. is a clinical-stage biotechnology company based in Cleveland, Ohio, founded in 2007. The company specializes in developing non-viral gene therapies aimed at activating the body's natural repair processes. Its primary focus is on treating non-healing wounds in patients with advanced peripheral artery disease. The flagship product, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1 (SDF-1), a signaling protein that helps recruit the body's stem cells and promotes tissue repair across various disease states. Juventas has transitioned its therapeutic platform from concept to the initiation of mid-stage clinical trials, underpinned by exclusive licensing from the Cleveland Clinic and supported by various investors and grants.

Celleration Inc. is a privately held medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, utilizes low-frequency ultrasound delivered through a saline mist to promote healing in wounds. This innovative approach allows ultrasound energy to penetrate beyond the surface of the wound, stimulating cellular activity and enhancing the healing process. Since receiving FDA clearance in 2005, Celleration has established a strong presence in the U.S. market, with over 1 million MIST Therapy treatments performed, benefiting more than 65,000 patients across numerous healthcare facilities. Celleration's commitment to advancing wound care technology has resulted in significant clinical and economic benefits, reinforcing its role in the medical community.

CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.

Tolera Therapeutics Inc. is a biotechnology company established under the leadership of Dr. Maria Siemionow, an expert in microsurgery and transplantation. Originating as a spin-off of the Cleveland Clinic, Tolera focuses on developing advanced immune modulation therapies aimed at enhancing organ and tissue transplant acceptance while minimizing the need for chronic immunosuppression. The company’s innovative approach targets the human alpha-beta T-cell receptor, which helps render pathologic T-cells inert. This unique signaling pathway promotes the expansion of regulatory T-cells in a non-depleting manner, addressing unmet medical needs for patients with a range of autoimmune and immune-mediated diseases. Through its research, Tolera Therapeutics aims to provide safer, more effective solutions that improve patient outcomes and quality of life.

CS-Keys is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer.

HydroCision, Inc. is a medical device company specializing in the development and commercialization of fluid jet-based surgical tools, particularly for the spine market. Founded in 1994 and headquartered in North Billerica, Massachusetts, the company offers innovative products such as the TenJet System, which utilizes ultrasound guidance for the percutaneous treatment of chronic tendon pain across various applications, and the SpineJet HydroDiscectomy System, designed for minimally invasive disc decompression procedures without the risks associated with thermal energy. Additional offerings include the SpineJet Fusion System, which prepares intervertebral disc spaces for graft implantation, and the AlloJet system for soft tissue debridement from donor bones. HydroCision’s technology enables precise tissue removal while minimizing damage to surrounding structures, thereby improving surgical outcomes. The company serves hospitals and physicians through its dedicated sales representatives.

Mitralign is a privately held medical device company based in a suburb of Boston, Massachusetts. It specializes in developing catheter-based technologies for the percutaneous treatment of functional mitral regurgitation, a global and life-threatening cardiac condition. The company's innovative Mitralign system mimics surgical annuloplasty by delivering a series of implants directly into the mitral annulus via a catheter, reducing its size and improving valve function. Mitralign is backed by top-tier venture capitalists and has strategic investments from major cardiovascular device companies.

BioVex Group is a biotechnology company specializing in the development and commercialization of biological treatments for cancer and infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine designed to target and destroy cancer cells while preserving surrounding healthy tissues. This innovative therapy utilizes a virus that replicates within solid tumors, leading to their destruction and stimulating a robust systemic immune response against the cancer. OncoVEXGM-CSF has undergone extensive clinical testing with over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and resulting in overall disease responses during Phase II trials. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes, further expanding its portfolio in biologic therapies.

Alluxa, Inc. is a manufacturer of precision optical thin film interference filters, primarily serving markets in industrial technology, telecommunications, biomedical instruments, and semiconductors. Founded in 2007 and based in Santa Rosa, California, the company specializes in designing and building coating equipment that utilizes automation and proprietary control algorithms. Alluxa employs a patented plasma thin film deposition process, enabling the company to offer customized precision coating solutions that meet high-performance requirements while maintaining cost-efficiency for its clients. Formerly known as Sirrus Technology, Inc., Alluxa has established itself as a significant player in its industry.

Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.

HydroCision, Inc. is a medical device company specializing in the development and commercialization of fluid jet-based surgical tools, particularly for the spine market. Founded in 1994 and headquartered in North Billerica, Massachusetts, the company offers innovative products such as the TenJet System, which utilizes ultrasound guidance for the percutaneous treatment of chronic tendon pain across various applications, and the SpineJet HydroDiscectomy System, designed for minimally invasive disc decompression procedures without the risks associated with thermal energy. Additional offerings include the SpineJet Fusion System, which prepares intervertebral disc spaces for graft implantation, and the AlloJet system for soft tissue debridement from donor bones. HydroCision’s technology enables precise tissue removal while minimizing damage to surrounding structures, thereby improving surgical outcomes. The company serves hospitals and physicians through its dedicated sales representatives.

HydroCision, Inc. is a medical device company specializing in the development and commercialization of fluid jet-based surgical tools, particularly for the spine market. Founded in 1994 and headquartered in North Billerica, Massachusetts, the company offers innovative products such as the TenJet System, which utilizes ultrasound guidance for the percutaneous treatment of chronic tendon pain across various applications, and the SpineJet HydroDiscectomy System, designed for minimally invasive disc decompression procedures without the risks associated with thermal energy. Additional offerings include the SpineJet Fusion System, which prepares intervertebral disc spaces for graft implantation, and the AlloJet system for soft tissue debridement from donor bones. HydroCision’s technology enables precise tissue removal while minimizing damage to surrounding structures, thereby improving surgical outcomes. The company serves hospitals and physicians through its dedicated sales representatives.

Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.

Mitralign is a privately held medical device company based in a suburb of Boston, Massachusetts. It specializes in developing catheter-based technologies for the percutaneous treatment of functional mitral regurgitation, a global and life-threatening cardiac condition. The company's innovative Mitralign system mimics surgical annuloplasty by delivering a series of implants directly into the mitral annulus via a catheter, reducing its size and improving valve function. Mitralign is backed by top-tier venture capitalists and has strategic investments from major cardiovascular device companies.

Mitralign is a privately held medical device company based in a suburb of Boston, Massachusetts. It specializes in developing catheter-based technologies for the percutaneous treatment of functional mitral regurgitation, a global and life-threatening cardiac condition. The company's innovative Mitralign system mimics surgical annuloplasty by delivering a series of implants directly into the mitral annulus via a catheter, reducing its size and improving valve function. Mitralign is backed by top-tier venture capitalists and has strategic investments from major cardiovascular device companies.

CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.

Kereos, Inc. is a biopharmaceutical company based in St. Louis, Missouri, specializing in the development of nanoscale drug delivery technologies and molecular imaging agents aimed at the detection and treatment of cancer and cardiovascular diseases. Founded in 1999, Kereos focuses on targeted delivery systems that enhance the effectiveness of therapeutic compounds, including existing drugs and novel candidates, particularly those that are too toxic or fragile for conventional delivery methods. The company's product portfolio includes KER-1001 and KER-1002, both cancer therapeutics utilizing natural products with demonstrated anti-tumor efficacy, and KER-1003, which targets angiogenesis. Additionally, Kereos offers diagnostic applications, such as KER 0001, an imaging platform for detecting angiogenesis. The company is also engaged in developing partnerships with pharmaceutical and imaging firms to advance its molecular imaging systems and cardiovascular disease MRI agents, thereby broadening its impact in the healthcare sector.

Renal Solutions is a company based in Warrendale, Pennsylvania, that specializes in the development of dialysis products and services. Founded in 2000, the company focuses on creating integrated medical devices for sorbent hemodialysis treatment, which is designed to improve care for patients suffering from chronic and acute kidney failure. By offering a clinical care model, Renal Solutions enables healthcare practitioners to provide convenient and flexible treatment options that utilize sorbent-based dialysis technology. In November 2007, Renal Solutions was acquired by Fresenius Medical Care, enhancing its capacity to deliver innovative renal care solutions.

Remon Medical Technologies is a development-stage company based in Caesarea, Israel, specializing in communication technology for medical device applications. It focuses on creating innovative miniature implants and medical devices to improve patient monitoring. The company's flagship products include RemonCHF, which is designed to monitor the hemodynamic status of patients suffering from congestive heart failure, and RemonAAA, a device that tracks pressure levels following endograft procedures in patients with abdominal aortic aneurysms. Through its advanced monitoring solutions, Remon Medical Technologies aims to enhance patient care and outcomes in critical healthcare scenarios.